Han, Anna
Chua, Vivian
Baqai, Usman
Purwin, Timothy J. http://orcid.org/0000-0002-7053-8039
Bechtel, Nelisa
Hunter, Emily
Tiago, Manoela
Seifert, Erin
Speicher, David W.
Schug, Zachary T. http://orcid.org/0000-0003-4197-8227
Harbour, J. William http://orcid.org/0000-0002-1104-9809
Aplin, Andrew E. http://orcid.org/0000-0002-2734-3244
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA196278, R01 CA253977, P01 CA114046)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Melanoma Research Alliance (559058, 559058)
American Association for Cancer Research
U.S. Department of Health & Human Services | National Institutes of Health (P01CA140043, S10OD023586)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 25 February 2021
Revised: 2 December 2021
Accepted: 10 December 2021
First Online: 20 January 2022
Competing interests
: AEA reports receiving a commercial research grant from Pfizer Inc. (2013–2017) and has ownership interest in patent number 9880150. JWH is the inventor of intellectual property related to prognostic testing for uveal melanoma. He is a paid consultant for Castle Biosciences, licensee of this intellectual property, and he receives royalties from its commercialization. The other authors disclose no potential conflicts of interest.